Annual report pursuant to Section 13 and 15(d)

Segment Reporting

v3.19.3.a.u2
Segment Reporting
12 Months Ended
Nov. 30, 2019
Segment Reporting [Abstract]  
Segment Reporting
Note 6
Segment Reporting
During the third quarter of fiscal 2018, the Company purchased the assets and assumed contracts that Cord:Use used in the operation of its cord blood business (See Note 2). The Company evaluated and determined that this acquisition qualifies as a separate segment.
The Company is organized in three reportable segments:
 
  1.
The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”).
 
  2.
The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte CB units (the “PrepaCyte CB”).
 
  3.
The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States, and around the world.
 
The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, income tax (expense) benefit, other comprehensive loss, and assets for the years ended November 30, 201
9
and 201
8
:
 
     For the years ended November 30,  
     2019      2018  
Net revenue:
     
Umbilical cord blood and cord tissue stem cell service
   $ 30,991,972      $ 28,817,872  
PrepaCyte CB
     172,395        104,323  
Public cord blood banking
     652,204        296,295  
  
 
 
    
 
 
 
Total net revenue
   $ 31,816,571      $ 29,218,490  
  
 
 
    
 
 
 
Cost of sales:
     
Umbilical cord blood and cord tissue stem cell service
   $ 8,490,824      $ 7,744,208  
PrepaCyte CB
     249,487        169,397  
Public cord blood banking
     1,295,864        626,057  
  
 
 
    
 
 
 
Total cost of sales
   $ 10,036,175      $ 8,539,662  
  
 
 
    
 
 
 
Operating profit:
     
Umbilical cord blood and cord tissue stem cell service
   $ 8,152,475      $ 5,620,394  
PrepaCyte CB
     (113,346      (101,329
Public cord blood banking
     (2,976,423      (329,762
  
 
 
    
 
 
 
Total operating profit
   $ 5,062,706      $ 5,189,303  
  
 
 
    
 
 
 
Depreciation and amortization:
     
Umbilical cord blood and cord tissue stem cell service
   $ 365,057      $ 281,072  
PrepaCyte CB
     36,254        36,254  
Public cord blood banking
            —    
  
 
 
    
 
 
 
Total depreciation and amortization
   $ 401,311      $ 317,326  
  
 
 
    
 
 
 
Interest expense:
     
Umbilical cord blood and cord tissue stem cell service
   $ 1,703,446      $ 1,546,900  
PrepaCyte CB
            —    
Public cord blood banking
            —    
  
 
 
    
 
 
 
Total interest expense
   $ 1,703,446      $ 1,546,900  
  
 
 
    
 
 
 
Income tax (expense) benefit:
     
 
 
 
Umbilical cord blood and cord tissue stem cell service
   $ (1,100,641    $ (4,472,504
 
 
 
 
 
 
 
 
 
PrepaCyte CB
            —    
Public cord blood banking
            —    
  
 
 
    
 
 
 
Total income tax (expense) benefit
   $ (1,100,641    $ (4,472,504
  
 
 
    
 
 
 
Other comprehensive income (loss):
     
Umbilical cord blood and cord tissue stem cell service
   $      $ 300,119  
PrepaCyte CB
            —    
Public cord blood banking
            —    
 
 
 
 
 
 
 
 
 
Total other comprehensive income (loss)
   $      $ 300,119  
  
 
 
    
 
 
 
The following table shows the assets by segment as of November 30, 2019 and November 30, 2018:
 
 
 
2019
 
 
2018
 
Assets:
  
     
  
     
Umbilical cord blood and cord tissue stem cell service
   $ 28,975,002      $ 26,239,260  
PrepaCyte CB
     289,804        319,802  
Public cord blood banking
     13,621,354        15,831,081  
  
 
 
    
 
 
 
Total assets
   $ 42,886,160      $ 42,390,143